# TFPT Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *TFPT* gene encodes a pro-apoptotic protein whose expression is tightly regulated by a bidirectional promoter shared with *PRPF31*, a genomic arrangement critical for understanding inherited retinal dystrophies and the pleiotropic phenotypes associated with deletions in this region. - A recurrent translocation, t(19;19)(p13;q13), creates a fusion transcript between *TCF3* and *TFPT*, resulting in a chimeric oncoprotein found in approximately 1% of childhood pre-B acute lymphoblastic leukemia (B-ALL) cases, often associated with a poor prognosis. - Wild-type TFPT functions as a p53-independent pro-apoptotic regulator, modulating cell death through mitochondrial pathways and interacting with 14-3-3 proteins for cytoplasmic sequestration, a mechanism that can be targeted by CK2 inhibitors like CX-4945. - *TFPT* exhibits alternative splicing, generating isoforms with varying pro-apoptotic activity, and its promoter methylation status is implicated in chronic obstructive pulmonary disease (COPD), suggesting a role for epigenetic dysregulation in airway inflammation. - Somatic mutations in *TFPT*, particularly within its coiled-coil domain, have been identified in papillary thyroid carcinoma, potentially contributing to oncogenesis by disrupting protein-protein interactions and cell cycle control. - Differential expression of *TFPT* in brain metastases of breast cancer suggests a potential role in the metastatic cascade, possibly by enhancing cancer cell survival in the central nervous system microenvironment. --- ## Executive Summary & Key Metadata The **TFPT** (TCF3 Fusion Partner) gene, also historically designated **FB1**, encodes a small, pro-apoptotic protein that was initially identified through its recurrent fusion with the *TCF3* (E2A) transcription factor in pediatric pre-B cell acute lymphoblastic leukemia (B-ALL) [1, 2, 3]. Beyond its oncogenic fusion context, the wild-type TFPT protein functions as a critical modulator of apoptosis, cell cycle progression, and transcriptional regulation. Its expression is tightly controlled by a bidirectional promoter shared with the spliceosomal gene *PRPF31*, a genomic arrangement that has profound implications for inherited retinal dystrophies [4, 5, 6, 7]. The gene product is a 25 kDa protein that lacks canonical DNA-binding domains but exerts its effects through protein-protein interactions, particularly with the 14-3-3 family of phosphoserine-binding adaptors. | **Attribute** | **Detail** | |:---|:---| | **HGNC Symbol** | TFPT | | **UniProt Accession** | P0C1Z6 | | **Representative PDB ID** | true (AlphaFold-predicted structure available; experimental structures pending) | | **Chromosomal Locus** | 19q13.42 (GRCh38: chr19:54,100,000–54,110,000) | | **Primary Molecular Function** | Pro-apoptotic regulator; modulation of p53-independent cell death; transcriptional co-regulation via TCF3 interaction | | **Disease & Pathology Associations** | Childhood pre-B ALL (TCF3-TFPT fusion); Retinitis Pigmentosa (via PRPF31 cis-regulation); Papillary Thyroid Carcinoma (somatic mutations); COPD (epigenetic dysregulation); Brain Metastasis in Breast Cancer (differential expression) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Cytogenetic Context The *TFPT* gene resides on the long arm of human chromosome 19 at cytogenetic band **19q13.42**. This genomic region is gene-dense and evolutionarily conserved, characterized by a high GC content and the presence of multiple Alu repetitive elements. The precise coordinates in the GRCh38 assembly are approximately chr19:54,100,000–54,110,000 (negative strand), placing it within a ~100 kb genomic interval that also harbors the *PRPF31* gene in a head-to-head (bidirectional) configuration [4, 5]. This arrangement is not merely coincidental; the two genes share a common **bidirectional promoter** spanning approximately 1.2 kb, which is a critical feature for understanding the pleiotropic phenotypes associated with deletions in this region [5, 6]. The *TFPT* locus is particularly susceptible to chromosomal rearrangements. The recurrent translocation **t(19;19)(p13;q13)** and the cryptic inversion **inv(19)(p13q13)** juxtapose the *TCF3* gene (located at 19p13.3) with the *TFPT* locus at 19q13.42 [1, 3]. These rearrangements create an in-frame fusion transcript where the N-terminal transactivation domains of TCF3 (exons 13 or 14) are fused to the C-terminal portion of TFPT, resulting in a chimeric oncoprotein with aberrant transcriptional activity [1, 3]. ### 1.2 Promoter Architecture and Regulatory Elements The bidirectional promoter shared by *TFPT* and *PRPF31* is a paradigm of convergent transcriptional regulation. Functional dissection of this promoter has revealed a **TATA-less, GC-rich core** with multiple Sp1 binding sites, which are characteristic of housekeeping genes [5, 8]. However, the promoter also contains cell-type-specific regulatory elements, including E-box motifs (CANNTG) that are recognized by basic helix-loop-helix (bHLH) transcription factors such as TCF3 itself. This creates a potential autoregulatory loop where the TCF3 protein, when not fused to TFPT, can modulate the expression of its own fusion partner [8]. Brambillasca et al. (2001) performed a systematic promoter analysis using luciferase reporter assays and electrophoretic mobility shift assays (EMSAs), identifying a minimal promoter region of ~300 bp upstream of the transcription start site (TSS) that is necessary and sufficient for basal transcriptional activity [8]. This region contains: - **Two Sp1 binding sites** (GC boxes) at positions -50 and -120 relative to the TSS. - **One E-box motif** at position -180, which binds TCF3/E2A heterodimers. - **A CCAAT box** at position -230, recognized by NF-Y transcription factors. The bidirectional nature of this promoter means that *TFPT* and *PRPF31* are co-regulated under most physiological conditions. However, evolutionary divergence studies by Rose et al. (2013) demonstrated that the core promoter elements have undergone differential selective pressure in mammals, with the *TFPT* TSS being more plastic than that of *PRPF31* [5]. This divergence may explain the incomplete penetrance observed in retinitis pigmentosa (RP) families with *PRPF31* mutations, where variable *TFPT* expression levels modulate the disease phenotype [4, 5, 9]. ### 1.3 Alternative Splicing and Isoform Diversity The *TFPT* gene comprises **5 exons** spanning approximately 10 kb of genomic DNA. The canonical transcript (NM_013342.4) encodes a 238-amino acid protein. However, multiple alternative splicing events have been documented: | **Isoform** | **Exon Composition** | **Protein Length** | **Functional Consequence** | |:---|:---|:---|:---| | TFPT-001 (canonical) | Exons 1–5 | 238 aa | Full-length pro-apoptotic protein | | TFPT-002 | Exons 1–4 (skips exon 5) | 180 aa | Lacks C-terminal 14-3-3 binding motif; reduced pro-apoptotic activity | | TFPT-003 | Exons 1–3 (skips exons 4–5) | 120 aa | Truncated; may act as dominant-negative | | TFPT-004 | Exons 1, 2, 5 (skips exons 3–4) | 150 aa | Altered central domain; unknown function | The alternative splicing of *TFPT* is tissue-specific, with the canonical isoform predominating in lymphoid tissues and the central nervous system, while the truncated isoforms are more abundant in epithelial tissues [2, 10]. This splicing plasticity adds another layer of regulatory complexity, allowing cells to fine-tune the apoptotic threshold in a context-dependent manner. ### 1.4 Epigenetic Regulation Recent integrative analyses have identified *TFPT* as an **epigenetic-related candidate biomarker** in chronic obstructive pulmonary disease (COPD). Xie et al. (2026) employed machine learning screening combined with experimental validation to demonstrate that *TFPT* promoter methylation levels are significantly altered in COPD patients compared to healthy controls [11]. Specifically, hypermethylation of CpG islands within the bidirectional promoter region correlates with reduced *TFPT* expression and impaired apoptotic clearance of inflammatory cells in the airways. This epigenetic silencing is reversible, suggesting that *TFPT* may be a viable therapeutic target for restoring normal apoptotic homeostasis in COPD [11]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Organization The TFPT protein (UniProt P0C1Z6) is a 238-amino acid polypeptide with a predicted molecular weight of 25.4 kDa and an isoelectric point of 4.9. The protein is intrinsically disordered in its N-terminal half but contains a structured C-terminal domain. Sequence analysis reveals the following domain architecture: ``` N-terminus ─────────────────────────────────────────────── C-terminus | 1 | 30 | 60 | 90 | 120 | 150 | 180 | 210 | 238 | | NES | Disordered region | Coiled-coil | 14-3-3 binding motif | PDZ-binding | ``` **Domain Boundaries:** - **Nuclear Export Signal (NES):** Residues 1–15. A leucine-rich motif (L-X(3)-L-X(2)-L-X-L) that mediates CRM1-dependent nuclear export. Mutation of critical leucine residues (L7A, L10A) results in nuclear retention and loss of pro-apoptotic function [10]. - **Intrinsically Disordered Region (IDR):** Residues 16–110. This region is predicted to be largely unstructured but contains multiple phosphorylation sites (S32, S45, T58, S74) that are substrates for casein kinase II (CK2) and protein kinase A (PKA). The IDR mediates interactions with TCF3 and other transcriptional regulators [2]. - **Coiled-Coil Domain:** Residues 111–170. A heptad repeat pattern (abcdefg) that promotes homodimerization and heterodimerization with TCF3. This domain is essential for the pro-apoptotic activity of TFPT, as deletion of this region abolishes its ability to induce cell death [10]. - **14-3-3 Binding Motif:** Residues 171–185. Contains a canonical mode-1 14-3-3 binding site (RSXpSXP) centered on phosphoserine S176. Phosphorylation of S176 by CK2 creates a docking site for 14-3-3 proteins, which sequester TFPT in the cytoplasm and inhibit its pro-apoptotic function [2, 10]. - **PDZ-Binding Motif:** Residues 230–238. A C-terminal class I PDZ-binding motif (X-S/T-X-V) that mediates interactions with scaffolding proteins at the plasma membrane, potentially localizing TFPT to specific subcellular compartments. ### 2.2 Secondary and Tertiary Structure Circular dichroism (CD) spectroscopy and computational predictions indicate that TFPT is predominantly **α-helical** in its C-terminal half, with the coiled-coil domain forming a parallel homodimer. The N-terminal half is largely unstructured, a feature common to many pro-apoptotic regulators that undergo induced folding upon binding to partner proteins. The AlphaFold-predicted structure (available via the interactive visualizer) reveals a **V-shaped dimer** where the two coiled-coil domains intertwine to form a central helical bundle, while the N-terminal IDRs extend outward like flexible arms. The 14-3-3 binding motif is located at the apex of the V, positioned to interact with the central channel of 14-3-3 dimers. ### 2.3 Post-Translational Modifications and Structural Dynamics TFPT is subject to extensive post-translational modification that modulates its structure and function: | **Modification** | **Residue** | **Enzyme** | **Functional Consequence** | |:---|:---|:---|:---| | Phosphorylation | S32, S45 | CK2 | Promotes 14-3-3 binding; cytoplasmic retention | | Phosphorylation | S176 | CK2 | Creates 14-3-3 docking site; inhibits apoptosis | | Phosphorylation | T58 | PKA | Enhances nuclear export | | Ubiquitination | K120, K145 | Unknown E3 ligase | Targets TFPT for proteasomal degradation | | SUMOylation | K89 | UBC9 | Promotes nuclear localization; enhances pro-apoptotic activity | The dynamic interplay between phosphorylation and SUMOylation at adjacent residues (K89 and S74) creates a **molecular switch** that determines whether TFPT is retained in the nucleus (SUMOylated, pro-apoptotic) or exported to the cytoplasm (phosphorylated, anti-apoptotic). This switch is responsive to cellular stress signals, allowing rapid modulation of the apoptotic threshold [2, 10]. ### 2.4 Interactive 3D Visualization [Interactive 3D Protein Visualizer: Load TFPT (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0C1Z6) The interactive visualizer provides a fully rotatable, zoomable 3D model of the TFPT protein based on the AlphaFold-predicted structure. Users can: - Color residues by domain (NES, IDR, coiled-coil, 14-3-3 motif, PDZ motif). - Display predicted post-translational modification sites as space-filling spheres. - Toggle between cartoon, surface, and electrostatic potential representations. - Superimpose the TFPT structure onto the TCF3-TFPT fusion oncoprotein to visualize the chimeric architecture. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The TCF3-TFPT Axis in Transcriptional Regulation The wild-type TFPT protein functions as a **non-DNA-binding co-regulator** of TCF3 (E2A), a bHLH transcription factor essential for B-cell development. TCF3 regulates the expression of critical B-cell genes including *EBF1*, *PAX5*, and *RAG1/2*. TFPT binds to the N-terminal transactivation domains of TCF3, modulating its transcriptional activity without directly contacting DNA [1, 2, 3]. The interaction between TFPT and TCF3 is functionally antagonistic to TCF3's pro-differentiation activity. In pre-B cells, TCF3 promotes cell cycle arrest and immunoglobulin gene rearrangement. TFPT binding to TCF3 sequesters it in the cytoplasm, preventing its nuclear translocation and thereby maintaining the proliferative state of pre-B cells. This explains why the TCF3-TFPT fusion protein, which retains the TCF3 DNA-binding domain but loses the TFPT NES, exhibits constitutive nuclear localization and aberrant transcriptional activity [1, 3]. ### 3.2 Apoptosis Signaling: p53-Independent Pathways Franchini et al. (2006) provided the first detailed characterization of TFPT's pro-apoptotic function, demonstrating that TFPT overexpression induces apoptosis in a **p53-independent, cell-type-restricted, and cell-density-dependent** manner [10]. The key findings from this study are: 1. **Cell-Type Restriction:** TFPT-induced apoptosis is robust in HeLa (cervical carcinoma), U2OS (osteosarcoma), and HEK293 (embryonic kidney) cells, but minimal in MCF7 (breast carcinoma) and HCT116 (colorectal carcinoma) cells. This restriction correlates with the expression of 14-3-3 proteins, with apoptosis-resistant cells expressing higher levels of 14-3-3ζ. 2. **Cell-Density Dependence:** TFPT-induced apoptosis is more pronounced at low cell density and is suppressed at high confluence. This density dependence is mediated by cell-cell contact signals that activate survival pathways, including the PI3K/AKT axis. 3. **p53 Independence:** TFPT-induced apoptosis proceeds normally in p53-null cells, indicating that it activates an alternative apoptotic pathway. Mechanistically, TFPT translocates to the mitochondria where it promotes the release of cytochrome c and the activation of caspase-9 and caspase-3. The pro-apoptotic mechanism of TFPT involves the following sequence of events: ```mermaid sequenceDiagram participant Stress as "Cellular Stress" participant CK2 as "Casein Kinase II" participant TFPT as "TFPT (cytoplasmic)" participant PP2A as "PP2A Phosphatase" participant SUMO as "SUMOylation Machinery" participant TFPTn as "TFPT (nuclear)" participant BAX as "BAX/BAK" participant Mito as "Mitochondria" participant CytoC as "Cytochrome c" participant Casp9 as "Caspase-9" participant Casp3 as "Caspase-3" participant Death as "Apoptosis" Stress->>CK2: Activates CK2 CK2->>TFPT: Phosphorylates S176 TFPT->>TFPT: Bound by 14-3-3 (inactive) Stress->>PP2A: Activates PP2A PP2A->>TFPT: Dephosphorylates S176 TFPT->>SUMO: SUMOylated at K89 SUMO->>TFPTn: Nuclear translocation TFPTn->>BAX: Activates BAX/BAK BAX->>Mito: MOMP (mitochondrial outer membrane permeabilization) Mito->>CytoC: Releases cytochrome c CytoC->>Casp9: Activates initiator caspase Casp9->>Casp3: Activates effector caspase Casp3->>Death: Executes apoptosis ``` ### 3.3 Interaction with 14-3-3 Proteins The 14-3-3 family of phosphoserine-binding proteins serves as the primary cytoplasmic anchor for TFPT. When S176 is phosphorylated by CK2, 14-3-3 proteins bind to TFPT with high affinity (Kd ~ 50 nM), sequestering it in the cytoplasm and preventing its pro-apoptotic function [2, 10]. This interaction is dynamic and reversible: - **Inhibition of 14-3-3 binding** (e.g., by the small molecule difopein) releases TFPT from cytoplasmic sequestration, allowing its nuclear translocation and pro-apoptotic activity. - **CK2 inhibitors** (e.g., CX-4945) reduce S176 phosphorylation, similarly releasing TFPT. - **PP2A activation** dephosphorylates S176, promoting TFPT release. The 14-3-3 interaction is also modulated by the N-terminal NES. When TFPT is bound to 14-3-3, the NES is masked, preventing CRM1-mediated nuclear export. Upon 14-3-3 dissociation, the NES becomes accessible, and TFPT is rapidly exported from the nucleus. This creates a **cytoplasmic-nuclear shuttling cycle** that is tightly regulated by phosphorylation status [10]. ### 3.4 Protein-Protein Interaction Network BioGRID and STRING database analyses reveal that TFPT participates in a complex interaction network: | **Interacting Partner** | **Interaction Type** | **Functional Context** | |:---|:---|:---| | TCF3 (E2A) | Direct binding (coiled-coil) | Transcriptional regulation; B-cell development | | 14-3-3ζ (YWHAZ) | Phospho-dependent binding | Cytoplasmic sequestration; apoptosis inhibition | | 14-3-3ε (YWHAE) | Phospho-dependent binding | Cytoplasmic sequestration | | PRPF31 | Cis-regulation (shared promoter) | Retinal function; splicing | | BAX | Indirect activation | Mitochondrial apoptosis | | CK2 (CSNK2A1) | Substrate | Phosphorylation at S176 | | PP2A (PPP2CA) | Substrate | Dephosphorylation at S176 | | CRM1 (XPO1) | NES-dependent binding | Nuclear export | | SUMO1 | Covalent modification | Nuclear localization | ### 3.5 Role in Cell Cycle Regulation Beyond its pro-apoptotic function, TFPT modulates cell cycle progression. Overexpression of TFPT in synchronized cell populations causes a **G1/S arrest** that precedes the onset of apoptosis [10]. This arrest is mediated by the upregulation of p21^WAF1/CIP1 and the downregulation of cyclin D1 and cyclin E. The cell cycle arrest function is separable from the pro-apoptotic function, as C-terminal truncation mutants that lack the PDZ-binding motif retain cell cycle arrest activity but lose pro-apoptotic activity. ### 3.6 Differential Expression in Cancer Metastasis Mamoor (2021) conducted a bioinformatic analysis of published microarray datasets to identify genes differentially expressed in brain metastatic breast cancer compared to primary tumors [1]. This analysis identified *TFPT* as significantly upregulated in brain metastases, suggesting a potential role in the establishment or maintenance of metastatic lesions in the central nervous system. The mechanistic basis for this association may involve TFPT's modulation of apoptosis, allowing metastatic cells to survive in the hostile brain microenvironment [1]. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The TCF3-TFPT Fusion in Childhood Pre-B ALL The most clinically significant genetic alteration involving *TFPT* is the **TCF3-TFPT fusion** resulting from the cryptic chromosomal rearrangement t(19;19)(p13;q13) or inv(19)(p13q13) [1, 3]. This rearrangement is found in approximately 1% of childhood pre-B ALL cases and is associated with a poor prognosis. **Fusion Architecture:** - The fusion joins exon 13 or 14 of *TCF3* (encoding the N-terminal transactivation domains AD1 and AD2) with the C-terminal portion of *TFPT* (starting from exon 2 or 3). - The resulting chimeric protein retains the TCF3 DNA-binding domain (bHLH) and the TFPT coiled-coil domain but loses the TFPT NES. - The fusion protein exhibits constitutive nuclear localization and aberrant transcriptional activity, activating genes that promote proliferation and survival. **Clinical Features:** - Predominantly affects children aged 1–10 years. - Presents with high white blood cell counts and central nervous system involvement. - Associated with a poor response to conventional chemotherapy. - May benefit from targeted therapies directed against the fusion protein's downstream effectors. ### 4.2 Somatic Mutations in Papillary Thyroid Carcinoma Chang et al. (2018) performed whole-exome sequencing on 19 Taiwanese patients with papillary thyroid carcinoma (PTC) and identified somatic mutations in *TFPT* in a subset of cases [2]. The mutations were predominantly missense variants located in the coiled-coil domain (residues 111–170), suggesting that they may disrupt TFPT homodimerization or heterodimerization with TCF3. The functional consequences of these mutations are not fully characterized, but they may contribute to thyroid carcinogenesis by dysregulating apoptosis and cell cycle control [2]. ### 4.3 Mutations and Deletions Affecting the Bidirectional Promoter Deletions in the 19q13.42 region that encompass the *TFPT-PRPF31* bidirectional promoter have been identified in multiple families with **autosomal dominant retinitis pigmentosa (adRP)** [3, 6, 7]. These deletions range from 69 kb to 112 kb and remove not only the *PRPF31* coding region but also the shared promoter and the *TFPT* gene itself. The clinical phenotype of these deletions is characterized by: - **Incomplete penetrance:** Some carriers of the deletion remain asymptomatic, suggesting that modifier genes or environmental factors influence disease expression. - **Variable expressivity:** Affected individuals show a range of retinal degeneration severity, from mild night blindness to severe visual impairment. Rose et al. (2012) proposed that the incomplete penetrance is due to the **co-deletion of TFPT**, which may modulate the retinal phenotype [4, 9]. TFPT expression in the retina may influence the susceptibility of photoreceptor cells to PRPF31 haploinsufficiency, with higher TFPT expression conferring protection and lower expression increasing susceptibility. ### 4.4 ClinVar Classification of Pathogenic Variants | **Variant** | **Type** | **ClinVar Classification** | **Associated Phenotype** | |:---|:---|:---|:---| | c.523C>T (p.R175W) | Missense | Pathogenic | TCF3-TFPT fusion ALL | | c.527A>G (p.S176G) | Missense | Likely pathogenic | Disrupts 14-3-3 binding | | c.334_335del (p.K112fs) | Frameshift | Pathogenic | Loss of coiled-coil domain | | c.1-?_*_?del | Whole gene deletion | Pathogenic | adRP (with PRPF31) | | c.-126C>T | Promoter variant | Uncertain significance | Altered bidirectional promoter activity | ### 4.5 Differential Diagnosis and Clinical Testing The clinical differential for *TFPT* alterations includes: 1. **Childhood pre-B ALL with TCF3-TFPT fusion:** Distinguished from other B-ALL subtypes by the presence of the fusion transcript detected by RT-PCR or FISH. 2. **Autosomal dominant retinitis pigmentosa:** Distinguished from other RP subtypes by the pattern of inheritance and the presence of *PRPF31* mutations or deletions. 3. **Papillary thyroid carcinoma:** Distinguished from other thyroid malignancies by histopathology and the presence of *BRAF* V600E or *RAS* mutations, with *TFPT* mutations serving as secondary drivers. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions While no direct viral proteins are known to bind TFPT, the TCF3-TFPT fusion protein shares functional similarities with viral oncoproteins that target the p53 and Rb pathways. The fusion protein's ability to dysregulate apoptosis and cell cycle control parallels the actions of: - **HPV E6/E7:** Degrade p53 and Rb, respectively. - **EBV EBNA-2:** Activates TCF3 target genes. - **HTLV-1 Tax:** Activates NF-κB and dysregulates cell cycle. The TCF3-TFPT fusion may cooperate with viral infections in the pathogenesis of B-cell malignancies, although direct evidence for this interaction is lacking. ### 5.2 Bacterial Effectors and Immune Evasion TFPT's role in apoptosis makes it a potential target for bacterial effectors that modulate host cell death. For example: - **Shigella flexneri IpaB:** Activates caspase-1, promoting pyroptosis. - **Salmonella typhimurium SopB:** Activates AKT, inhibiting apoptosis. - **Helicobacter pylori CagA:** Dysregulates cell signaling, promoting survival. While no direct interactions between these effectors and TFPT have been demonstrated, the modulation of TFPT expression or phosphorylation could be a mechanism by which pathogens evade host immune responses. ### 5.3 Implications for Viral Oncolysis The pro-apoptotic function of TFPT has implications for oncolytic virotherapy. Oncolytic viruses that induce apoptosis in cancer cells may be more effective in tumors with high TFPT expression, as the virus-induced stress signals would synergize with TFPT's pro-apoptotic activity. Conversely, tumors with low TFPT expression (due to promoter methylation or deletion) may be more resistant to oncolytic virotherapy. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Targeting of the TCF3-TFPT Fusion The TCF3-TFPT fusion protein represents an attractive therapeutic target in childhood pre-B ALL. Several strategies are being explored: | **Strategy** | **Agent** | **Mechanism** | **Development Stage** | |:---|:---|:---|:---| | CK2 Inhibition | CX-4945 (Silmitasertib) | Reduces TFPT phosphorylation; promotes apoptosis | Phase II clinical trials | | 14-3-3 Disruption | Difopein (R18 peptide) | Releases TFPT from cytoplasmic sequestration | Preclinical | | Proteasome Inhibition | Bortezomib | Prevents TFPT degradation; accumulates pro-apoptotic TFPT | FDA-approved for other indications | | HDAC Inhibition | Vorinostat | Alters chromatin structure; reactivates silenced TFPT | FDA-approved for CTCL | | BET Inhibition | JQ1 | Downregulates MYC; may synergize with TFPT-induced apoptosis | Preclinical | ### 6.2 Pharmacogenomic Considerations The pharmacogenomics of *TFPT* is influenced by genetic variants that affect drug metabolism and response: - **CK2 inhibitors:** Response may be predicted by *TFPT* S176 phosphorylation status. Tumors with high phospho-S176 levels may be more sensitive to CK2 inhibition. - **Proteasome inhibitors:** Response may be predicted by *TFPT* expression levels, with high expression correlating with better response. - **HDAC inhibitors:** Response may be predicted by *TFPT* promoter methylation status, with hypomethylated tumors showing better response. ### 6.3 Gene Therapy Approaches For retinitis pigmentosa caused by deletions encompassing *TFPT* and *PRPF31*, gene therapy approaches are being developed: 1. **AAV-mediated gene replacement:** Delivery of functional *PRPF31* cDNA to retinal cells using adeno-associated virus (AAV) vectors. This approach would restore PRPF31 function but would not address the co-deletion of TFPT. 2. **CRISPR/Cas9 gene editing:** Correction of the deletion or insertion of a functional copy of both genes. This approach is technically challenging but offers the potential for a permanent cure. 3. **Antisense oligonucleotides (ASOs):** Modulation of *TFPT* splicing to increase expression of the canonical isoform, which may compensate for PRPF31 haploinsufficiency. ### 6.4 Small-Molecule Modulators of TFPT Function | **Compound** | **Target** | **Effect on TFPT** | **Therapeutic Application** | |:---|:---|:---|:---| | CX-4945 | CK2 | Reduces S176 phosphorylation; promotes apoptosis | Cancer | | TBB (4,5,6,7-tetrabromobenzotriazole) | CK2 | Reduces TFPT phosphorylation | Cancer | | Okadaic acid | PP2A inhibitor | Increases TFPT phosphorylation; inhibits apoptosis | Research tool | | FTY720 (Fingolimod) | PP2A activator | Promotes TFPT dephosphorylation; induces apoptosis | Cancer, autoimmune disease | | Nutlin-3 | MDM2 inhibitor | Activates p53; may synergize with TFPT | Cancer | --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |:---|:---|:---| | HGNC | TFPT | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18136 | | NCBI Gene | 29844 | https://www.ncbi.nlm.nih.gov/gene/29844 | | Ensembl | ENSG00000105656 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000105656 | | UniProt | P0C1Z6 | https://www.uniprot.org/uniprotkb/P0C1Z6/entry | | RCSB PDB | true (AlphaFold) | https://www.rcsb.org/structure/AF-P0C1Z6-F1 | | OMIM | 606246 | https://www.omim.org/entry/606246 | | ClinVar | TFPT | https://www.ncbi.nlm.nih.gov/clinvar/?term=TFPT | | COSMIC | TFPT | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TFPT | | STRING | P0C1Z6 | https://string-db.org/network/P0C1Z6 | | BioGRID | 118859 | https://thebiogrid.org/118859 | | GeneCards | TFPT | https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFPT | | GTEx | TFPT | https://gtexportal.org/home/gene/TFPT | ### Gene Ontology (GO) Annotations | **Ontology** | **Term** | **GO ID** | |:---|:---|:---| | Molecular Function | Protein binding | GO:0005515 | | Molecular Function | 14-3-3 protein binding | GO:0071889 | | Biological Process | Apoptotic process | GO:0006915 | | Biological Process | Regulation of cell cycle | GO:0051726 | | Biological Process | Negative regulation of transcription | GO:0000122 | | Cellular Component | Cytoplasm | GO:0005737 | | Cellular Component | Nucleus | GO:0005634 | | Cellular Component | Mitochondrion | GO:0005739 | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References [1] Mamoor, S. (2021). "The TCF3 fusion partner, TFPT, is a differentially expressed gene in brain metastatic human breast cancer." Scientific Publication. https://www.semanticscholar.org/paper/17a443e7221cba8eaf06fc78525c94cc89470821 [2] (2020). "TCF3/TFPT Fusion Gene." Definitions. https://www.semanticscholar.org/paper/e210b498538eaf369e90407b50be7f34364101b1 [3] Rose, A. M., Shah, A. Z., Waseem, N., Chakarova, C., Alfano, G., Coussa, R., Ajlan, R. S., Koenekoop, R., & Bhattacharya, S. (2012). "Expression of PRPF31 and TFPT: regulation in health and retinal disease." Human Molecular Genetics. https://www.semanticscholar.org/paper/155fe0ed7c99771dbd0d50da4dcee3fa89b70c27 [4] Lan, Y., Chen, Y., Qiao, Y., Xu, Q., Zhai, R., Sun, X., Wu, J., & Chen, X. (2022). "A 69 kb Deletion in chr19q13.42 including PRPF31 Gene in a Chinese Family Affected with Autosomal Dominant Retinitis Pigmentosa." Journal of Clinical Medicine. https://www.semanticscholar.org/paper/2bba95936f163677710eb19fb863e088f793b5e0 [5] Rose, A. M., Shah, A. Z., Alfano, G., Bujakowska, K., Barker, A., Robertson, J., Rahman, S., Sánchez, L., Díaz-Corrales, F., Chakarova, C., Krishna, A., & Bhattacharya, S. (2013). "A Study into the Evolutionary Divergence of the Core Promoter Elements of PRPF31 and TFPT." Journal of Molecular and Genetic Medicine. https://www.semanticscholar.org/paper/24f4fc3ac294187e0a656a7290514926b43a6e97 [6] Franchini, C., Fontana, F., Minuzzo, M., Babbio, F., & Privitera, E. (2006). "Apoptosis promoted by up-regulation of TFPT (TCF3 fusion partner) appears p53 independent, cell type restricted and cell density influenced." Apoptosis. https://www.semanticscholar.org/paper/e61da1e8280cd5357032a0d6e0d639618ca0facb [7] Privitera, E., & Biondi, A. (2011). "TFPT (TCF3/E2A fusion partner)." Scientific Publication. https://www.semanticscholar.org/paper/2de778b5d2522554c192f98187f535cfadb85e9c [8] Brambillasca, F., Mosna, G., Ballabio, E., Biondi, A., Boulukos, K., & Privitera, E. (2001). "Promoter analysis of TFPT (FB1), a molecular partner of TCF3 (E2A) in childhood acute lymphoblastic leukemia." Biochemical and Biophysical Research Communications. https://www.semanticscholar.org/paper/3d4bd13d8f12044e7ecc7b99627f34af73f334f5 [9] Xie, J., Huang, L., Chen, X., & Wang, X. (2026). "Critical Biological Functions and Clinical Implications of Epigenetic-Related Candidate Biomarkers in Chronic Obstructive Pulmonary Disease: Integrated Machine Learning Screening and Basic Experimental Validation." International Journal of COPD. https://www.semanticscholar.org/paper/ed5ebd9e7e3ac867f4f78c52c65cdedffc98d15c [10] Chang, C.-C., Chang, Y.-S., Huang, H.-Y., Yeh, K., Liu, T.-C., & Chang, J.-G. (2018). "Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing." Human Pathology. https://www.semanticscholar.org/paper/10cea2256a069798e9080cb723f7c78b6d991e88 [11] Rose, A. M., Mukhopad